H2N2V1, PubMed, Checkpoint, bibRecord, 000036

Evaluation of multivalent H2 influenza pandemic vaccines in mice.

Identifieur interne : 000036 ( PubMed/Checkpoint ); précédent : 000035; suivant : 000037

Evaluation of multivalent H2 influenza pandemic vaccines in mice.

Auteurs : Brian J. Lenny [États-Unis] ; Stephanie Sonnberg [États-Unis] ; Angela F. Danner [États-Unis] ; Kimberly Friedman [États-Unis] ; Richard J. Webby [États-Unis] ; Robert G. Webster [États-Unis] ; Jeremy C. Jones [États-Unis]

Source :

Vaccine [ 1873-2518 ] ; 2017.

RBID : pubmed:28189402

Descripteurs français

KwdFr :
- Animaux, Femelle, Grippe humaine (), Grippe humaine (anatomopathologie), Humains, Immunité humorale, Modèles animaux de maladie humaine, Pandémies (), Souris de lignée BALB C, Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (immunologie), Vaccins antigrippaux (isolement et purification), Vaccins inactivés (administration et posologie), Vaccins inactivés (immunologie), Vaccins inactivés (isolement et purification), Virus de la grippe A (immunologie).
MESH :
- administration et posologie : Vaccins antigrippaux, Vaccins inactivés.
- anatomopathologie : Grippe humaine.
- immunologie : Vaccins antigrippaux, Vaccins inactivés, Virus de la grippe A.
- isolement et purification : Vaccins antigrippaux, Vaccins inactivés.
- Animaux, Femelle, Grippe humaine, Humains, Immunité humorale, Modèles animaux de maladie humaine, Pandémies, Souris de lignée BALB C.

English descriptors

KwdEn :
- Animals, Disease Models, Animal, Female, Humans, Immunity, Humoral, Influenza A virus (immunology), Influenza Vaccines (administration & dosage), Influenza Vaccines (immunology), Influenza Vaccines (isolation & purification), Influenza, Human (pathology), Influenza, Human (prevention & control), Mice, Inbred BALB C, Pandemics (prevention & control), Vaccines, Inactivated (administration & dosage), Vaccines, Inactivated (immunology), Vaccines, Inactivated (isolation & purification).
MESH :
- chemical , administration & dosage : Influenza Vaccines, Vaccines, Inactivated.
- immunology : Influenza A virus, Influenza Vaccines, Vaccines, Inactivated.
- chemical , isolation & purification : Influenza Vaccines, Vaccines, Inactivated.
- pathology : Influenza, Human.
- prevention & control : Influenza, Human, Pandemics.
- Animals, Disease Models, Animal, Female, Humans, Immunity, Humoral, Mice, Inbred BALB C.

Abstract

Subtype H2 Influenza A viruses were the cause of a severe pandemic in the winter of 1957. However, this subtype no longer circulates in humans and is no longer included in seasonal vaccines. As a result, individuals under 50years of age are immunologically naïve. H2 viruses persist in aquatic birds, which were a contributing source for the 1957 pandemic, and have also been isolated from swine. Reintroduction of the H2 via zoonotic transmission has been identified as a pandemic risk, so pre-pandemic planning should include preparation and testing of vaccine candidates against this subtype. We evaluated the immunogenicity of two inactivated, whole virus influenza vaccines (IVV) in mice: a monovalent IVV containing human pandemic virus A/Singapore/1/1957 (H2N2), and a multivalent IVV containing human A/Singapore/1/1957, avian A/Duck/HongKong/319/1978 (H2N2), and swine A/Swine/Missouri/2124514/2006 (H2N3) viruses. While both vaccines induced protective immunity compared to naïve animals, the multivalent formulation was advantageous over the monovalent in terms of level and breadth of serological responses, neutralization of infectious virus, and reduction of clinical disease and respiratory tissue replication in mice. Therefore, multivalent pandemic H2 vaccines containing diverse viruses from animal reservoirs, are a potential option to improve the immune responses in a pre-pandemic scenario where antigenic identity cannot be predicted.

DOI: 10.1016/j.vaccine.2017.01.026
PubMed: 28189402

Affiliations:

États-Unis

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 000039
to stream PubMed, to step Curation: 000039

Links to Exploration step

pubmed:28189402

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Evaluation of multivalent H2 influenza pandemic vaccines in mice.</title>
<author><name sortKey="Lenny, Brian J" sort="Lenny, Brian J" uniqKey="Lenny B" first="Brian J" last="Lenny">Brian J. Lenny</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases, Division of Virology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Infectious Diseases, Division of Virology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105</wicri:regionArea>
<wicri:noRegion>TN 38105</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sonnberg, Stephanie" sort="Sonnberg, Stephanie" uniqKey="Sonnberg S" first="Stephanie" last="Sonnberg">Stephanie Sonnberg</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases, Division of Virology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Infectious Diseases, Division of Virology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105</wicri:regionArea>
<wicri:noRegion>TN 38105</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Danner, Angela F" sort="Danner, Angela F" uniqKey="Danner A" first="Angela F" last="Danner">Angela F. Danner</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases, Division of Virology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Infectious Diseases, Division of Virology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105</wicri:regionArea>
<wicri:noRegion>TN 38105</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Friedman, Kimberly" sort="Friedman, Kimberly" uniqKey="Friedman K" first="Kimberly" last="Friedman">Kimberly Friedman</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases, Division of Virology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Infectious Diseases, Division of Virology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105</wicri:regionArea>
<wicri:noRegion>TN 38105</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Webby, Richard J" sort="Webby, Richard J" uniqKey="Webby R" first="Richard J" last="Webby">Richard J. Webby</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases, Division of Virology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Infectious Diseases, Division of Virology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105</wicri:regionArea>
<wicri:noRegion>TN 38105</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Webster, Robert G" sort="Webster, Robert G" uniqKey="Webster R" first="Robert G" last="Webster">Robert G. Webster</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases, Division of Virology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Infectious Diseases, Division of Virology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105</wicri:regionArea>
<wicri:noRegion>TN 38105</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jones, Jeremy C" sort="Jones, Jeremy C" uniqKey="Jones J" first="Jeremy C" last="Jones">Jeremy C. Jones</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases, Division of Virology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Infectious Diseases, Division of Virology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105</wicri:regionArea>
<wicri:noRegion>TN 38105</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:28189402</idno>
<idno type="pmid">28189402</idno>
<idno type="doi">10.1016/j.vaccine.2017.01.026</idno>
<idno type="wicri:Area/PubMed/Corpus">000039</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000039</idno>
<idno type="wicri:Area/PubMed/Curation">000039</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000039</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000036</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000036</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Evaluation of multivalent H2 influenza pandemic vaccines in mice.</title>
<author><name sortKey="Lenny, Brian J" sort="Lenny, Brian J" uniqKey="Lenny B" first="Brian J" last="Lenny">Brian J. Lenny</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases, Division of Virology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Infectious Diseases, Division of Virology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105</wicri:regionArea>
<wicri:noRegion>TN 38105</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sonnberg, Stephanie" sort="Sonnberg, Stephanie" uniqKey="Sonnberg S" first="Stephanie" last="Sonnberg">Stephanie Sonnberg</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases, Division of Virology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Infectious Diseases, Division of Virology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105</wicri:regionArea>
<wicri:noRegion>TN 38105</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Danner, Angela F" sort="Danner, Angela F" uniqKey="Danner A" first="Angela F" last="Danner">Angela F. Danner</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases, Division of Virology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Infectious Diseases, Division of Virology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105</wicri:regionArea>
<wicri:noRegion>TN 38105</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Friedman, Kimberly" sort="Friedman, Kimberly" uniqKey="Friedman K" first="Kimberly" last="Friedman">Kimberly Friedman</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases, Division of Virology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Infectious Diseases, Division of Virology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105</wicri:regionArea>
<wicri:noRegion>TN 38105</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Webby, Richard J" sort="Webby, Richard J" uniqKey="Webby R" first="Richard J" last="Webby">Richard J. Webby</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases, Division of Virology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Infectious Diseases, Division of Virology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105</wicri:regionArea>
<wicri:noRegion>TN 38105</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Webster, Robert G" sort="Webster, Robert G" uniqKey="Webster R" first="Robert G" last="Webster">Robert G. Webster</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases, Division of Virology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Infectious Diseases, Division of Virology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105</wicri:regionArea>
<wicri:noRegion>TN 38105</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jones, Jeremy C" sort="Jones, Jeremy C" uniqKey="Jones J" first="Jeremy C" last="Jones">Jeremy C. Jones</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases, Division of Virology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Infectious Diseases, Division of Virology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105</wicri:regionArea>
<wicri:noRegion>TN 38105</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Vaccine</title>
<idno type="eISSN">1873-2518</idno>
<imprint><date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Disease Models, Animal</term>
<term>Female</term>
<term>Humans</term>
<term>Immunity, Humoral</term>
<term>Influenza A virus (immunology)</term>
<term>Influenza Vaccines (administration & dosage)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Influenza Vaccines (isolation & purification)</term>
<term>Influenza, Human (pathology)</term>
<term>Influenza, Human (prevention & control)</term>
<term>Mice, Inbred BALB C</term>
<term>Pandemics (prevention & control)</term>
<term>Vaccines, Inactivated (administration & dosage)</term>
<term>Vaccines, Inactivated (immunology)</term>
<term>Vaccines, Inactivated (isolation & purification)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Femelle</term>
<term>Grippe humaine ()</term>
<term>Grippe humaine (anatomopathologie)</term>
<term>Humains</term>
<term>Immunité humorale</term>
<term>Modèles animaux de maladie humaine</term>
<term>Pandémies ()</term>
<term>Souris de lignée BALB C</term>
<term>Vaccins antigrippaux (administration et posologie)</term>
<term>Vaccins antigrippaux (immunologie)</term>
<term>Vaccins antigrippaux (isolement et purification)</term>
<term>Vaccins inactivés (administration et posologie)</term>
<term>Vaccins inactivés (immunologie)</term>
<term>Vaccins inactivés (isolement et purification)</term>
<term>Virus de la grippe A (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term>
<term>Vaccines, Inactivated</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term>
<term>Vaccins inactivés</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Vaccins antigrippaux</term>
<term>Vaccins inactivés</term>
<term>Virus de la grippe A</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A virus</term>
<term>Influenza Vaccines</term>
<term>Vaccines, Inactivated</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="isolation & purification" xml:lang="en"><term>Influenza Vaccines</term>
<term>Vaccines, Inactivated</term>
</keywords>
<keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Vaccins antigrippaux</term>
<term>Vaccins inactivés</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term>
<term>Pandemics</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Disease Models, Animal</term>
<term>Female</term>
<term>Humans</term>
<term>Immunity, Humoral</term>
<term>Mice, Inbred BALB C</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Femelle</term>
<term>Grippe humaine</term>
<term>Humains</term>
<term>Immunité humorale</term>
<term>Modèles animaux de maladie humaine</term>
<term>Pandémies</term>
<term>Souris de lignée BALB C</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Subtype H2 Influenza A viruses were the cause of a severe pandemic in the winter of 1957. However, this subtype no longer circulates in humans and is no longer included in seasonal vaccines. As a result, individuals under 50years of age are immunologically naïve. H2 viruses persist in aquatic birds, which were a contributing source for the 1957 pandemic, and have also been isolated from swine. Reintroduction of the H2 via zoonotic transmission has been identified as a pandemic risk, so pre-pandemic planning should include preparation and testing of vaccine candidates against this subtype. We evaluated the immunogenicity of two inactivated, whole virus influenza vaccines (IVV) in mice: a monovalent IVV containing human pandemic virus A/Singapore/1/1957 (H2N2), and a multivalent IVV containing human A/Singapore/1/1957, avian A/Duck/HongKong/319/1978 (H2N2), and swine A/Swine/Missouri/2124514/2006 (H2N3) viruses. While both vaccines induced protective immunity compared to naïve animals, the multivalent formulation was advantageous over the monovalent in terms of level and breadth of serological responses, neutralization of infectious virus, and reduction of clinical disease and respiratory tissue replication in mice. Therefore, multivalent pandemic H2 vaccines containing diverse viruses from animal reservoirs, are a potential option to improve the immune responses in a pre-pandemic scenario where antigenic identity cannot be predicted.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28189402</PMID>
<DateCompleted><Year>2017</Year>
<Month>12</Month>
<Day>13</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>35</Volume>
<Issue>10</Issue>
<PubDate><Year>2017</Year>
<Month>03</Month>
<Day>07</Day>
</PubDate>
</JournalIssue>
<Title>Vaccine</Title>
<ISOAbbreviation>Vaccine</ISOAbbreviation>
</Journal>
<ArticleTitle>Evaluation of multivalent H2 influenza pandemic vaccines in mice.</ArticleTitle>
<Pagination><MedlinePgn>1455-1463</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2017.01.026</ELocationID>
<Abstract><AbstractText>Subtype H2 Influenza A viruses were the cause of a severe pandemic in the winter of 1957. However, this subtype no longer circulates in humans and is no longer included in seasonal vaccines. As a result, individuals under 50years of age are immunologically naïve. H2 viruses persist in aquatic birds, which were a contributing source for the 1957 pandemic, and have also been isolated from swine. Reintroduction of the H2 via zoonotic transmission has been identified as a pandemic risk, so pre-pandemic planning should include preparation and testing of vaccine candidates against this subtype. We evaluated the immunogenicity of two inactivated, whole virus influenza vaccines (IVV) in mice: a monovalent IVV containing human pandemic virus A/Singapore/1/1957 (H2N2), and a multivalent IVV containing human A/Singapore/1/1957, avian A/Duck/HongKong/319/1978 (H2N2), and swine A/Swine/Missouri/2124514/2006 (H2N3) viruses. While both vaccines induced protective immunity compared to naïve animals, the multivalent formulation was advantageous over the monovalent in terms of level and breadth of serological responses, neutralization of infectious virus, and reduction of clinical disease and respiratory tissue replication in mice. Therefore, multivalent pandemic H2 vaccines containing diverse viruses from animal reservoirs, are a potential option to improve the immune responses in a pre-pandemic scenario where antigenic identity cannot be predicted.</AbstractText>
<CopyrightInformation>Copyright © 2017 The Author(s). Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Lenny</LastName>
<ForeName>Brian J</ForeName>
<Initials>BJ</Initials>
<AffiliationInfo><Affiliation>Department of Infectious Diseases, Division of Virology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Biology, Rhodes College, 2000 North Parkway, Memphis, TN 38112, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y" EqualContrib="Y"><LastName>Sonnberg</LastName>
<ForeName>Stephanie</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Department of Infectious Diseases, Division of Virology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Danner</LastName>
<ForeName>Angela F</ForeName>
<Initials>AF</Initials>
<AffiliationInfo><Affiliation>Department of Infectious Diseases, Division of Virology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Friedman</LastName>
<ForeName>Kimberly</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Department of Infectious Diseases, Division of Virology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Webby</LastName>
<ForeName>Richard J</ForeName>
<Initials>RJ</Initials>
<AffiliationInfo><Affiliation>Department of Infectious Diseases, Division of Virology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Webster</LastName>
<ForeName>Robert G</ForeName>
<Initials>RG</Initials>
<AffiliationInfo><Affiliation>Department of Infectious Diseases, Division of Virology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Jones</LastName>
<ForeName>Jeremy C</ForeName>
<Initials>JC</Initials>
<AffiliationInfo><Affiliation>Department of Infectious Diseases, Division of Virology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>HHSN272201400006C</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2017</Year>
<Month>02</Month>
<Day>08</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Vaccine</MedlineTA>
<NlmUniqueID>8406899</NlmUniqueID>
<ISSNLinking>0264-410X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D056724" MajorTopicYN="N">Immunity, Humoral</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009980" MajorTopicYN="N">Influenza A virus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">H2N2</Keyword>
<Keyword MajorTopicYN="Y">Influenza</Keyword>
<Keyword MajorTopicYN="Y">Monovalent</Keyword>
<Keyword MajorTopicYN="Y">Multivalent</Keyword>
<Keyword MajorTopicYN="Y">Pandemic</Keyword>
<Keyword MajorTopicYN="Y">Vaccine</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year>
<Month>02</Month>
<Day>08</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2016</Year>
<Month>12</Month>
<Day>16</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2017</Year>
<Month>01</Month>
<Day>11</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2017</Year>
<Month>2</Month>
<Day>13</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2017</Year>
<Month>12</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2017</Year>
<Month>2</Month>
<Day>13</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">28189402</ArticleId>
<ArticleId IdType="doi">10.1016/j.vaccine.2017.01.026</ArticleId>
<ArticleId IdType="pmc">PMC5336516</ArticleId>
<ArticleId IdType="mid">NIHMS847399</ArticleId>
<ArticleId IdType="pii">S0264-410X(17)30061-0</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Arch Virol. 2000;145(6):1059-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10948982</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2011 Mar 10;471(7337):157-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21390107</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virus Res. 2004 Jul;103(1-2):163-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15163505</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2015 Apr;89(8):4549-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25673719</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2008 Oct;8(10):650-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18922487</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Influenza Other Respir Viruses. 2013 Jan;7(1):66-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22417012</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2010 Aug;84(15):7695-702</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20504935</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 1999 Dec;80 ( Pt 12):3167-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10567648</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):11044-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20534457</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2012;7(7):e39990</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22808082</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2015 Feb;89(4):2442-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25505070</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccines (Basel). 2015 Apr 24;3(2):373-89</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26343192</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Top Microbiol Immunol. 2014;385:137-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25048542</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2010 Jun 21;5(6):e11158</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20574518</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2015 Dec;15(12):1459-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26362172</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Vaccine Immunol. 2006 Sep;13(9):981-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16960108</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Acta Virol. 1997 Oct;41(5):251-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9607078</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1989 Nov;63(11):4603-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2795713</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Med Res Methodol. 2010 Mar 08;10:18</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20210985</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2007 May 4;25(18):3554-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17293015</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2009 Feb 11;27(7):1050-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19095028</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2011 Oct 13;29(44):7696-703</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21839131</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Immunol. 2009 Jun;21(3):346-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19500964</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2015 Mar;477:61-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25659818</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2007 Apr;81(7):3514-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17251294</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2006 Jan;12(1):66-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16494720</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Acta Virol. 1992 Mar;36(2):113-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1279962</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2010 Feb;84(4):1715-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20007271</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Adv Virus Res. 2010;77:63-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20951870</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Vaccine Immunol. 2009 Apr;16(4):558-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19225073</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Pharm Biopharm. 2015 Aug;94:251-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26047796</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Hyg (Lond). 1985 Oct;95(2):437-45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4067298</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Chim Acta. 1991 May 15;198(3):183-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1716184</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2015 Jan 29;33(5):734-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25444791</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Drug Discov. 2015 Mar;14(3):167-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25722244</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2009 Jun 18;459(7249):931-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19525932</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2006 Nov 1;194 Suppl 2:S111-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17163383</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hum Vaccin. 2010 Oct;6(10):792-801</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20935469</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MBio. 2011 Aug 30;2(5):null</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21878571</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Vaccines. 2013 Sep;12(9):1085-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24024871</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hum Vaccin Immunother. 2015;11(4):970-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25831405</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Infect Dis. 2015 Oct 27;15:465</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26503131</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Vaccines. 2008 Aug;7(6):783-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18665776</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Infect Dis. 2015 Feb 26;15:101</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25887952</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 1998 Jul;178(1):53-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9652423</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2014 Mar;88(5):2867-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24371061</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Vaccines. 2013 May;12(5):519-36</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23659300</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20949-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18093945</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med Microbiol Immunol. 2002 Dec;191(3-4):203-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12458361</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 1999 Sep-Oct;5(5):659-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10511522</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Viruses. 2015 Aug 04;7(8):4369-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26248076</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Scand J Immunol. 2015 May;81(5):305-17</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25737202</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 1997 Feb;175(2):352-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9203656</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 1945 Jul;24(4):536-46</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16695243</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Wkly Epidemiol Rec. 2015 Mar 20;90(12):109-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25796641</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2014 Jan;88(2):1175-88</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24227848</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 1993 Jun;194(2):781-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7684877</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2015 Jan 1;33(1):193-200</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25444799</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
</list>
<tree><country name="États-Unis"><noRegion><name sortKey="Lenny, Brian J" sort="Lenny, Brian J" uniqKey="Lenny B" first="Brian J" last="Lenny">Brian J. Lenny</name>
</noRegion>
<name sortKey="Danner, Angela F" sort="Danner, Angela F" uniqKey="Danner A" first="Angela F" last="Danner">Angela F. Danner</name>
<name sortKey="Friedman, Kimberly" sort="Friedman, Kimberly" uniqKey="Friedman K" first="Kimberly" last="Friedman">Kimberly Friedman</name>
<name sortKey="Jones, Jeremy C" sort="Jones, Jeremy C" uniqKey="Jones J" first="Jeremy C" last="Jones">Jeremy C. Jones</name>
<name sortKey="Sonnberg, Stephanie" sort="Sonnberg, Stephanie" uniqKey="Sonnberg S" first="Stephanie" last="Sonnberg">Stephanie Sonnberg</name>
<name sortKey="Webby, Richard J" sort="Webby, Richard J" uniqKey="Webby R" first="Richard J" last="Webby">Richard J. Webby</name>
<name sortKey="Webster, Robert G" sort="Webster, Robert G" uniqKey="Webster R" first="Robert G" last="Webster">Robert G. Webster</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000036 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000036 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    H2N2V1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:28189402
   |texte=   Evaluation of multivalent H2 influenza pandemic vaccines in mice.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:28189402" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a H2N2V1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 14 19:59:40 2020. Site generation: Thu Mar 25 15:38:26 2021

	Serveur d'exploration H2N2
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration H2N2

Evaluation of multivalent H2 influenza pandemic vaccines in mice.

Evaluation of multivalent H2 influenza pandemic vaccines in mice.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki